KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $13.5 million.

  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) fell 467.25% to $13.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $55.7 million, marking a year-over-year decrease of 178.58%. This contributed to the annual value of $55.7 million for FY2025, which is 178.58% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $13.5 million for Q4 2025, which was down 467.25% from $13.8 million recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) peaked at $15.0 million during Q2 2024, and registered a low of $9.5 million during Q1 2022.
  • Its 5-year average for Depreciation & Amortization (CF) is $12.9 million, with a median of $13.5 million in 2023.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Depreciation & Amortization (CF) surged by 6551.95% in 2021 and then crashed by 2492.66% in 2022.
  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $11.4 million in 2021, then grew by 25.81% to $14.3 million in 2022, then dropped by 5.79% to $13.5 million in 2023, then rose by 5.09% to $14.2 million in 2024, then decreased by 4.67% to $13.5 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $13.5 million for Q4 2025, versus $13.8 million for Q3 2025 and $13.9 million for Q2 2025.